Merck's newly FDA-approved vaccine, Capvaxive, offers protection against 21 strains of pneumococcus, preventing serious illnesses like pneumonia in adults. Unlike existing shots, this is the first pneumococcal conjugate vaccine designed specifically for adults, providing broader protection. While pneumococcal disease can affect healthy adults, those with chronic health conditions are at higher risk for severe forms of the illness. Invasive pneumococcal disease can lead to meningitis and bloodstream infections, often resulting in hospitalization. With 150,000 U.S. adults hospitalized annually due to this disease, Merck's vaccine aims to reduce the burden on older populations. The CDC will determine eligibility for the single-dose vaccine, with Merck ready to supply by late summer. The vaccine aims to improve quality of life and prevent severe infections, especially in vulnerable populations.